NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa

21 Aug 2023
www.pmlive.com
Phase 3Drug ApprovalClinical Result
NICE recommends Amryt’s Filsuvez treatment for epidermolysis bullosa
Preview
Source: PMLiVE
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Amryt Pharmaceuticals’ Filsuvez (birch bark extract) for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa (EB).
Affecting around 500,000 people worldwide, EB is a rare inherited skin disorder that causes the skin to become fragile, causing blisters, tears and the loss of skin segments.
NICE’s decision marks the first time the institute has recommended an EB treatment, with around 670 patients in England expected to benefit from Filsuvez.
Helen Knight, director of health technology assessment at NICE, said: "There are substantial treatment requirements to manage [EB] symptoms. These include daily cleaning of wounds and dressing changes that can often total 37 hours a week and which themselves can cause substantial pain."
The recommendation follows positive results from the phase 3 birch bark extract clinical trial, EASE, which found that the treatment led to quicker wound healing in patients with dystrophic and junctional EB and had potential to reduce the amount of skin affected.
The EASE trial was the largest phase 3 randomised control trial to examine the efficacy and safety of Amryt’s Filsuvez gel/Oleogel-S10 in comparison to the control gel for EB.
Patients with EB from the EASE double-blind phase who received the treatment experienced a reduction in overall wound burdens, a reduced frequency of dressing changes, and were well tolerated, with a similar safety profile to control gel.
Dr Joe Wiley, chief executive of Amryt Pharma, commented on the EASE trial results, stating that they represented an "important advancement for patients and families living with this rare and distressing disorder".
Knight added: "[Filsuvez] has the potential to improve the quality of life for people with EB and their carers and help free up time for other activities" after receiving "valuable insight" from patients' experiences with EB from organisations including DEBRA and Genetic Alliance UK.
In June 2022, the European Commission approved Filsuvez in the EU for patients aged six months and older for partial-thickness wounds associated with dystrophic and junctional EB.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.